127 related articles for article (PubMed ID: 22505233)
1. Role of monocyte chemoattractant protein-1, tumor necrosis factor-alpha and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma.
Qian Q; Sun WK; Zhan P; Zhang Y; Song Y; Yu LK
Int J Biol Markers; 2012 Jul; 27(2):e118-24. PubMed ID: 22505233
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha promotes malignant pleural effusion.
Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of inflammatory cytokines in malignant and benign pleural effusions.
Alexandrakis MG; Coulocheri SA; Bouros D; Mandalaki K; Karkavitsas N; Eliopoulos GD
Oncol Rep; 2000; 7(6):1327-32. PubMed ID: 11032938
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
6. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.
Xu C; Yu L; Zhan P; Zhang Y
Eur J Med Res; 2014 May; 19(1):23. PubMed ID: 24887477
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q
Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042
[TBL] [Abstract][Full Text] [Related]
8. Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.
Yang G; Li H; Yao Y; Xu F; Bao Z; Zhou J
Oncol Rep; 2015 Jan; 33(1):478-84. PubMed ID: 25371165
[TBL] [Abstract][Full Text] [Related]
9. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
[TBL] [Abstract][Full Text] [Related]
10. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer.
Cheng D; Kong H; Li Y
Biomarkers; 2013 Aug; 18(5):386-90. PubMed ID: 23688054
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
13. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis.
Li X; Wan L; Shen H; Geng J; Nie J; Wang G; Jia N; Dai M; Bai X
J Thorac Oncol; 2012 Jan; 7(1):76-84. PubMed ID: 22011671
[TBL] [Abstract][Full Text] [Related]
14. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
Psallidas I; Stathopoulos GT; Maniatis NA; Magkouta S; Moschos C; Karabela SP; Kollintza A; Simoes DC; Kardara M; Vassiliou S; Papiris SA; Roussos C; Kalomenidis I
Oncogene; 2013 Jan; 32(4):528-35. PubMed ID: 22370646
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
16. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade.
Chen SF; Lin YS; Jao SW; Chang YC; Liu CL; Lin YJ; Nieh S
PLoS One; 2013; 8(5):e54659. PubMed ID: 23658677
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer.
Su WP; Chen YT; Lai WW; Lin CC; Yan JJ; Su WC
Lung Cancer; 2011 Jan; 71(1):28-33. PubMed ID: 20430468
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
Vazakidou ME; Magkouta S; Moschos C; Kalomenidis I
Respirology; 2014 Feb; 19(2):290-292. PubMed ID: 23819792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
